START-UP ’s monthly update on technology transfer deals--licensing agreements between companies and universities or other research institutions—in in vitro diagnostics, pharmaceuticals, research/analytical equipment & supplies, and medical devices.
Oxford Gene Technology licenses 12 cancer biomarkers from Inven2
Inven2 AS, the tech transfer arm of the University of Oslo and Oslo University Hospital, has granted...
Join thousands of industry professionals who rely on Scrip for daily insights
Already a subscriber?
UroGen’s Zusduri was approved despite an advisory committee vote recommending against it in May. It is the first approved drug for a type of recurring bladder cancer.
Private Company Edition: Antares’ lead asset will enter the clinic in 2026 after Lilly committed up to $2.5bn for Scorpion’s Phase I/II PI3Kα inhibitor STX-478. Also, Amplify raised $200m for its first biotech VC fund and Mosanna raised an $80m series A round, among other financings.
The Belgian drugmaker is boosting its biologics capacity over the pond.
